Reporter brief
RCT of rapamycin versus placebo for safety and feasibility in APOE4 carriers at Alzheimer's risk
What happened
This randomized controlled trial evaluated the safety, feasibility, and preliminary efficacy of low-dose daily rapamycin (1 mg) or fasting-mimicking diet (FMD) compared to placebo over 8 weeks in middle-aged adults carrying the APOE ε4 allele, a genetic risk factor for Alzheimer's disease. The study aimed to assess outcomes related to body, brain, and longevity in this at-risk population. No results of the intervention were reported in the abstract provided.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Middle-aged adults at elevated risk for Alzheimer's disease due to the apolipoprotein (APOE) ε4 allele
- Design
- Rct
- Sample
- —
- Journal
- Cedars-Sinai Medical Center
- Published
- Sep 16, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.